SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001610618-23-000086
Filing Date
2023-09-06
Accepted
2023-09-06 08:05:10
Documents
14
Period of Report
2023-09-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cdtx-20230906.htm   iXBRL 8-K 27921
2 PRESS RELEASE ex9912023-09x06.htm EX-99.1 12300
6 GRAPHIC cdtxlogoa18a.jpg GRAPHIC 63449
  Complete submission text file 0001610618-23-000086.txt   261259

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cdtx-20230906.xsd EX-101.SCH 1899
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cdtx-20230906_lab.xml EX-101.LAB 25156
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cdtx-20230906_pre.xml EX-101.PRE 13048
8 EXTRACTED XBRL INSTANCE DOCUMENT cdtx-20230906_htm.xml XML 2829
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

IRS No.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 231237888
SIC: 2836 Biological Products, (No Diagnostic Substances)